Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Applied Molecular Transport
South San Francisco, California, United Statesappliedmt.com ↗
- Ownership
- Public · AMTI
- Employees
- ~13
- Development stage
- Other
01
Overview
The lead program AMT‑101 completed four Phase 2 trials in ulcerative colitis. Results showed similar clinical remission rates between drug and placebo arms but demonstrated good tolerability. The second program, AMT‑126 targeting IL‑22 pathways for GI disorders, entered Phase 1a trials with plans for further development that were halted as part of strategic restructuring.
- Therapeutic areas
- GastroenterologyImmunology
- Modalities
- Oral biologics (proteins, peptides)Full-length antibodies and antibody fragmentsRNA therapeutics
- Industry
- Biotech
02
Partnerships
Merger agreement with Cyclo Therapeutics Inc.; no other major disclosed partnerships pre-merger.
Beyond the preview
Go deeper on Applied Molecular Transport.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Applied Molecular Transport.